Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 24, 2026, 11:47 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 361–384 of 4,589 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Crossover Clear all
Completed Phase 1 Interventional Accepts healthy volunteers

A Single Dose Crossover Study In Healthy Subjects To Evaluate Different Formulations Of PF-06882961

NCT03492697
View directory record Official record
Conditions
Healthy Subjects
Interventions
PF-06882961 Immediate Release Tablet, PF-06882961 Controlled Release Tablet (long), PF-06882961 Controlled Release Tablet (short), PF-06882961 Immediate Release Solution
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 55 Years
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Jul 30, 2018 · Synced Oct 24, 2026, 11:47 AM EDT
Completed Phase 3 Interventional Results available

A Trial Comparing the Safety and Efficacy of Insulin Degludec and Insulin Glargine, Both With Insulin Aspart as Mealtime Insulin in Subjects With Type 1 Diabetes

NCT02034513
View directory record Official record
Conditions
Diabetes, Diabetes Mellitus, Type 1
Interventions
insulin degludec, insulin glargine, insulin aspart
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
18 Years and older
Enrollment
501 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
92
States / cities
Birmingham, Alabama • Goodyear, Arizona • Concord, California + 81 more
Source: ClinicalTrials.gov public record
Updated Jan 2, 2019 · Synced Oct 24, 2026, 11:47 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Thorough QT Study of TR-701free Acid (FA) in Healthy Subjects

NCT01461460
View directory record Official record
Conditions
Healthy Volunteer
Interventions
TR-701 FA 1200 mg, Moxifloxacin 400 mg, TR-701 FA 200 mg plus Placebo, Placebo
Drug
Lead sponsor
Trius Therapeutics LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Industry
Eligibility
18 Years to 45 Years
Enrollment
48 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Dec 5, 2018 · Synced Oct 24, 2026, 11:47 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Phase 1 Study of Relative Bioavailability of PPI-668 Tablet and Capsule Formulations

NCT01979484
View directory record Official record
Conditions
Pharmacokinetic Assessments in Healthy Volunteers
Interventions
PPI-668 capsule, PPI-668 tablet
Drug
Lead sponsor
Presidio Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013
U.S. locations
1
States / cities
Buffalo, New York
Source: ClinicalTrials.gov public record
Updated Jan 9, 2014 · Synced Oct 24, 2026, 11:47 AM EDT
Completed Phase 1 Interventional

Bioequivalence & Food Effect Study in Patients With Solid Tumor or Hematologic Malignancies

NCT02223052
View directory record Official record
Conditions
Hematological Neoplasms, Non-Hodgkin's Lymphoma, Hodgkin's Lymphoma, Lymphoma, Multiple Myeloma, Acute Myeloid Leukemia, Leukemia, Myelodysplastic Syndromes, Neoplasms, Melanoma, Breast Cancer, Metastatic Breast Cancer, Non-Small Cell Lung Cancer, Small Cell Lung Cancer, Renal Cell Carcinoma, Glioblastoma Multiforme, Osteosarcoma, Sarcoma, Thyroid Cancer, Genitourinary
Interventions
CC-486, Vidaza
Drug
Lead sponsor
Celgene
Industry
Eligibility
18 Years and older
Enrollment
89 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
10
States / cities
Scottsdale, Arizona • Tucson, Arizona • Iowa City, Iowa + 6 more
Source: ClinicalTrials.gov public record
Updated May 12, 2020 · Synced Oct 24, 2026, 11:47 AM EDT
Completed Phase 1 Interventional

Trial to Assess the Pharmacokinetics, Safety, Tolerability of Oral Brexpiprazole in Children (6 to <13 Years Old) With Central Nervous System Disorders

NCT03292848
View directory record Official record
Conditions
ADHD, Autism, Bipolar I Disorder, Conduct Disorder, Oppositional Defiant Disorder
Interventions
Brexpiprazole
Drug
Lead sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
Industry
Eligibility
6 Years to 12 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
9
States / cities
Little Rock, Arkansas • Rogers, Arkansas • Long Beach, California + 4 more
Source: ClinicalTrials.gov public record
Updated Jun 12, 2018 · Synced Oct 24, 2026, 11:47 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Double Crossover Casein Type Tolerance Trial

NCT06315517
View directory record Official record
Conditions
Dairy Intolerance, Healthy Adults
Interventions
Conventional lactose-free cow's milk, Nonconventional (A2) cow's milk, Nonconventional (A2) lactose-free cow's milk
Other
Lead sponsor
Auburn University
Other
Eligibility
18 Years to 85 Years
Enrollment
48 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024
U.S. locations
1
States / cities
Auburn, Alabama
Source: ClinicalTrials.gov public record
Updated Apr 4, 2025 · Synced Oct 24, 2026, 11:47 AM EDT
Completed Not applicable Interventional

Dietary Supplementation in Heart Failure

NCT03980574
View directory record Official record
Conditions
Heart Failure
Interventions
R Drink
Dietary Supplement
Lead sponsor
Ohio State University
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Oct 22, 2021 · Synced Oct 24, 2026, 11:47 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Open-Label, Single-Dose Study to Evaluate the Safety and PK of DIC075V in Subjects With Renal Insufficiency and Hepatic Impairment Compared to Healthy Subjects and Evaluate the Safety and Pharmacokinetics of HPβCD When Administered in DIC075V Compared to Sporanox® in Healthy Subjects

NCT00805090
View directory record Official record
Conditions
Renal Insufficiency, Chronic, Hepatic Insufficiency, Healthy
Interventions
Sporanox, Diclofenac Sodium
Drug
Lead sponsor
Javelin Pharmaceuticals
Industry
Eligibility
18 Years to 75 Years
Enrollment
37 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2009
U.S. locations
3
States / cities
Orlando, Florida • Minneapolis, Minnesota • Knoxville, Tennessee
Source: ClinicalTrials.gov public record
Updated Apr 30, 2009 · Synced Oct 24, 2026, 11:47 AM EDT
Completed Phase 2 Interventional Results available

A Study of Regadenoson in Subjects Undergoing Stress Myocardial Perfusion Imaging (MPI) Using Multidetector Computed Tomography (MDCT) Compared to Single Photon Emission Computed Tomography (SPECT)

NCT01334918
View directory record Official record
Conditions
Coronary Artery Disease (CAD)
Interventions
regadenoson, technetium Tc99m sestamibi /technetium Tc99m tetrafosmin, Contrast, Single Photon Emission Computed Tomography, Multidetector Computed Tomography
Drug · Radiation · Procedure
Lead sponsor
Astellas Pharma Inc
Industry
Eligibility
45 Years and older
Enrollment
124 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
11
States / cities
Roseville, California • Torrance, California • Miami, Florida + 6 more
Source: ClinicalTrials.gov public record
Updated Dec 4, 2024 · Synced Oct 24, 2026, 11:47 AM EDT
Completed Not applicable Interventional

Hyperoxia on Ventilation During Recovery From General Anesthesia

NCT05922020
View directory record Official record
Conditions
Ventilatory Depression, Postoperative Respiratory Failure
Interventions
Oxygen gas
Other
Lead sponsor
Stanford University
Other
Eligibility
20 Years to 90 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Mar 13, 2024 · Synced Oct 24, 2026, 11:47 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Bioequivalency Study of Famciclovir 500 mg Tablets Under Fasted Conditions

NCT01321515
View directory record Official record
Conditions
Herpes
Interventions
famciclovir
Drug
Lead sponsor
Roxane Laboratories
Industry
Eligibility
18 Years to 45 Years
Enrollment
36 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007
U.S. locations
1
States / cities
Hackensack, New Jersey
Source: ClinicalTrials.gov public record
Updated Jan 23, 2018 · Synced Oct 24, 2026, 11:47 AM EDT
Terminated Phase 3 Interventional

Standard Therapy With or Without Surgery and Mitomycin C in Treating Patients With Advanced Limited Peritoneal Dissemination of Colon Cancer

NCT01167725
View directory record Official record
Conditions
Colorectal Cancer
Interventions
bevacizumab, cetuximab, FOLFIRI regimen, FOLFOX regimen, capecitabine, fluorouracil, irinotecan hydrochloride, leucovorin calcium, mitomycin C, oxaliplatin, therapeutic conventional surgery
Biological · Drug · Procedure
Lead sponsor
Alliance for Clinical Trials in Oncology
Other
Eligibility
18 Years to 120 Years
Enrollment
340 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
2
States / cities
Baltimore, Maryland • Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Dec 27, 2024 · Synced Oct 24, 2026, 11:47 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Cetylpyridium Chloride (CPC) Based Chewing Gum and Gingivitis

NCT03219840
View directory record Official record
Conditions
Gingivitis, Plaque, Dental, Periodontal Diseases
Interventions
Cetylpyridinium Chloride (CPC) 0.09% + Xylitol chewing gum, Xylitol only chewing gum
Drug
Lead sponsor
The University of Texas Health Science Center, Houston
Other
Eligibility
18 Years and older
Enrollment
70 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2018
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Feb 8, 2021 · Synced Oct 24, 2026, 11:47 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Study of Two Different Formulations of Pirtobrutinib (LOXO-305) In Healthy Participants

NCT06258174
View directory record Official record
Conditions
Healthy
Interventions
Pirtobrutinib
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years to 55 Years
Enrollment
28 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Jan 13, 2025 · Synced Oct 24, 2026, 11:47 AM EDT
Completed Phase 1 Interventional Results available

An fMRI Study Of Brain Response In Patients With Fibromyalgia

NCT00760474
View directory record Official record
Conditions
Fibromyalgia
Interventions
Pregabalin, then placebo, Placebo, then pregabalin
Drug
Lead sponsor
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Industry
Eligibility
18 Years to 70 Years · Female only
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
2
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Jan 22, 2021 · Synced Oct 24, 2026, 11:47 AM EDT
Recruiting Not applicable Interventional

Transitional Intervention for Hyperacusis in Autism

NCT07798297
View directory record Official record
Conditions
Loudness Hyperacusis, Autism Spectrum Disorder (ASD), Hyperacusis
Interventions
Transitional Intervention for Hyperacusis in Autism
Other
Lead sponsor
University of Central Florida
Other
Eligibility
18 Years to 39 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
2
States / cities
Orlando, Florida • Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Sep 1, 2026 · Synced Oct 24, 2026, 11:47 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Work Hour Reductions, Medical Errors, and Intern Well-Being at Providence St. Vincent Medical Center Intensive Care Unit

NCT00996320
View directory record Official record
Conditions
Sleep Deprivation, Depression
Interventions
Reduced work hour schedule
Other
Lead sponsor
Providence Health & Services
Other
Eligibility
Not listed
Enrollment
22 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2009
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Oct 16, 2009 · Synced Oct 24, 2026, 11:47 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Determine the Effect of Famotidine on the Drug Levels of BMS-986256 in Healthy Participants

NCT04941755
View directory record Official record
Conditions
Healthy Participants
Interventions
BMS-986256, Famotidine
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years to 55 Years
Enrollment
22 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Jan 21, 2022 · Synced Oct 24, 2026, 11:47 AM EDT
Completed Phase 2 Interventional Results available

Efficacy and Safety Study of Orvepitant for Chronic Cough in Patients With Idiopathic Pulmonary Fibrosis

NCT05185089
View directory record Official record
Conditions
Cough, Idiopathic Pulmonary Fibrosis
Interventions
Orvepitant Maleate, Placebo
Drug
Lead sponsor
Nerre Therapeutics Ltd.
Industry
Eligibility
40 Years and older
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
16
States / cities
Los Angeles, California • San Francisco, California • Denver, Colorado + 13 more
Source: ClinicalTrials.gov public record
Updated Nov 10, 2025 · Synced Oct 24, 2026, 11:47 AM EDT
Completed Not applicable Interventional Results available

Reducing Episodes by Septal Pacing Efficacy Confirmation Trial (RESPECT)

NCT00289289
View directory record Official record
Conditions
Atrial Fibrillation, Tachycardia, Supraventricular, Arrhythmia, Bradycardia
Interventions
Intervention Pacing Features
Device
Lead sponsor
Medtronic Cardiac Rhythm and Heart Failure
Industry
Eligibility
Not listed
Enrollment
400 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2011
U.S. locations
34
States / cities
Little Rock, Arkansas • Rancho Mirage, California • San Diego, California + 31 more
Source: ClinicalTrials.gov public record
Updated Aug 8, 2012 · Synced Oct 24, 2026, 11:47 AM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Spinal Cord Stimulation for Functional Recovery in Humans With Tetraplegia

NCT05157282
View directory record Official record
Conditions
Spinal Cord Injury
Interventions
TESS, Training, Motor Task, sham-TESS
Device · Other
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
18 Years to 70 Years
Enrollment
86 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2027
U.S. locations
2
States / cities
Chicago, Illinois • Hines, Illinois
Source: ClinicalTrials.gov public record
Updated Jan 16, 2026 · Synced Oct 24, 2026, 11:47 AM EDT
Completed Not applicable Interventional

An Intuitive, Non-intrusive, Approach to Reduce Patient Harm From Inappropriate Dosing of High-risk Drugs in Older Adult Patients Across an Urban Safety Net Hospital System

NCT05218343
View directory record Official record
Conditions
Potentially Inappropriate Medications
Interventions
EHR-based "nudge" interventions
Behavioral
Lead sponsor
Icahn School of Medicine at Mount Sinai
Other
Eligibility
65 Years and older
Enrollment
8,640 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022
U.S. locations
2
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Mar 17, 2023 · Synced Oct 24, 2026, 11:47 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Evaluation of the Performance of Different Daily Disposable Lens Designs in Habitual Soft Contact Lens Wearers

NCT04668989
View directory record Official record
Conditions
Myopia
Interventions
stenfilcon A - (Test lens), kalifilcon A - (Control Lens)
Device
Lead sponsor
CooperVision, Inc.
Industry
Eligibility
18 Years and older
Enrollment
68 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2021
U.S. locations
4
States / cities
Medina, Minnesota • Vestal, New York • Athens, Ohio + 1 more
Source: ClinicalTrials.gov public record
Updated Sep 16, 2021 · Synced Oct 24, 2026, 11:47 AM EDT